Sivik Global Healthcare Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$5.41M |
| 2 |
Revvity
RVTY
|
+$4.91M |
| 3 |
Zimmer Biomet
ZBH
|
+$4.67M |
| 4 |
HCA Healthcare
HCA
|
+$4.38M |
| 5 |
Abbott
ABT
|
+$4.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$9.29M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$6.42M |
| 3 |
Gilead Sciences
GILD
|
+$5.73M |
| 4 |
AstraZeneca
AZN
|
+$4.22M |
| 5 |
Johnson & Johnson
JNJ
|
+$4.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.35% |
| 2 | Financials | 3.26% |
| 3 | Energy | 1.24% |
| 4 | Consumer Staples | 0% |
| 5 | Industrials | 0% |
Similar funds
Sivik Global Healthcare's Q1 2017 Portfolio in Review
As of Q1 2017, Sivik Global Healthcare held 71 positions worth $215M, up 2.4% from $210M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Sivik Global Healthcare withdrew a net $12.1M in Q1 2017, closing 12 positions and reducing 23 holdings. Its most notable exit was iShares Biotechnology ETF, an estimated $9.29M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 83% a quarter earlier, followed by Financials and Energy.
Against the trend, Sivik Global Healthcare opened a new position in Baxter International worth $5.71M.
- Sivik Global Healthcare's largest Q1 2017 buy was Baxter International: 110,000 shares worth $5.71M.
- Sivik Global Healthcare added most to Eli Lilly in Q1 2017, an estimated $4M increase.
- Sivik Global Healthcare's biggest Q1 2017 reduction was AstraZeneca, cutting an estimated $4.22M.
- Sivik Global Healthcare fully exited iShares Biotechnology ETF in Q1 2017, selling an estimated $9.29M.
- Sivik Global Healthcare's ten largest holdings make up 32% of its $215M portfolio in Q1 2017.
- Sivik Global Healthcare opened 17 new positions and closed 12 in Q1 2017.
- Sivik Global Healthcare's portfolio value rose 2.4% quarter-over-quarter to $215M.
Based on Sivik Global Healthcare's 13F filing for Q1 2017, filed 11 May 2017.